The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS- 10504 tablets", a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced non-small cell lung cancer. The specific indication will be determined after the completion of clinical research.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
18.02 HKD | -1.64% | -0.99% | +14.21% |
04-30 | Hansoh Pharmaceutical’s 2023 Profit Up 27% | MT |
04-29 | Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+14.21% | 13.87B | |
+33.43% | 700B | |
+27.46% | 569B | |
-5.12% | 358B | |
+19.59% | 330B | |
+4.89% | 287B | |
+15.79% | 236B | |
+6.41% | 202B | |
-9.08% | 197B | |
+4.26% | 161B |
- Stock Market
- Equities
- 3692 Stock
- News Hansoh Pharmaceutical Group Company Limited
- Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung Cancer